Summary The expression of the EGF receptor, c-erbB-2 and PDGF receptor proteins has been studied in a series of human brain tumour biopsies and cell lines. Western blotting was used to determine the amount of protein present and their intrinsic and ligand promoted enzyme activities were studied by immunoprecipitation followed by autophosphorylation. EGF receptors were found to be expressed at very high levels in 40% of primary tumour biopsies, but at uniformly low levels in tumour derived cell lines. The c-erbB-2 protein was not detected in tumour biopsies, but was present at variable, but low levels in extracts of tumour cell lines. PDGF receptors were also found at moderate to low levels in both primary tumours and cell lines. The EGF receptor gene was amplified in four out of 14 primary tumours and this generally correlated with high levels of protein expression. The c-erbB-2 gene was not amplified. Employing the polymerase chain reaction and sequence specific oligonucleotides as probes there was no evidence of mutations in the c-erbB-2 gene transmembrane region. These results suggest that alterations of expression of the EGF receptor may play a role in human brain tumours. There was however no evidence for aberrant expression of the c-erbB-2 protein.
Several clhanges occurring at the level of DNA are thought to be required for full malignant transformation. One family of molecules known to be capable of influencing this process are the growth factor receptors. Much evidence has emerged for changes in the gene copy number, gene structure and level of expression of a subset of these in certain types of human cancers. The type one growth factor receptors, epidermal growth factor receptor and the c-erbB-2 protein are often overexpressed, predominantly in squamous cell carcinomas (Ozanne et al., 1986) and adenocarcinomas (Gullick & Venter, 1989) respectively.
Overexpression is often a consequence of gene amplification. Since this change very rarely happens in normal DNA ) it provides a strong indication of the aberrant nature of this event. In some cases however, elevated receptor expression occurs as a consequence of increased transcription which is less easy to characterise as abnormal (Kraus et al., 1987; Slamon et al., 1989) . Nonetheless, this may have a significant influence on the disease process.
Several reports have indicated that the EGF receptor is overexpressed at very high levels in some brain tumours as a consequence of gene amplification (Libermann et al., 1985; Wong et al., 1987) . Some evidence suggests that mRNA for the PDGF receptor and the PDGF A and B type growth factors are expressed at moderate to high levels in brain tumour biopsies (Hermansson et al., 1988; Nister et al., 1988) and cell lines (Harsh et al., 1989) . The c-erbB-2 protein is expressed in certain areas of normal human foetal brain but its possible role in human brain tumours has not been studied. We have examined the gene copy number, gene structure and level of protein expression of the EGF receptor, c-erbB-2 and PDGF receptor in a group of primary brain tumour biopsies and a series of brain tumour derived cell lines. In addition we have looked for potential activating mutations in the transmembrane sequence of the c-erbB-2 gene (Segatto et al., 1988) . Any changes in these systems may be useful for more accurately categorising tumours and provide targets for immunotherapy or inhibitors of receptor function.
Materials and methods
Collection, storage (Franks & Burrow, 1986) . Cell lines were employed for analysing receptor expression after between eight and 20 passages, depending on the particular cell line. Although none of these cell lines were cloned, they were established and the vast majority of the tumour cells in each culture exhibited a similar morphology at the time of lysis.
The diagnosis on the solid tumours were made by consultant neuropathologists at the National Hospitals for Nervous Diseases, Maida Vale and Queen Square, London. The classification was that described in Russel and Rubinstein (1977) .
Preparation ofprimary brain tumour and brain tumour cell line lysates Lysate from the cell lines were prepared and their protein concentration determined as described previously (Corbett et al., 1990 (Bowen-Pope et al., 1985) . Cells were labelled with 35S-methionine and immunoprecipitated as described previously (Waterfield et al., 1982 (Waterfield et al., 1982) , 21N or 22P to the EGF receptor, c-erbB-2 protein and PDGF receptor respectively. Control cell lines used were A431 (Waterfield et al., 1982) for EGF receptor, SKBR3 for c-erbB-2 PAGE sample buffer and boiling for 3 min.
Samples were run on a 5% polyacrylamide gel, stained with Coomassie blue, destained, dried and autoradiographed using Kodak XAR-5 film overnight at -80°C.
Western blotting
One hundred 1tg of total cell protein from primary brain tumours or 19 Lg from brain tumour cell lines were run on 5% polyacrylamide gels and transferred and detected as previously described .
Southern blotting DNA was extracted from the tumours, digested with EcoRI endonuclease, separated on a 0.8% agarose gel and transferred to Hybond-N (Amersham, UK) membranes. The blots were probed with purified insert of clone p64.1 from the EGF receptor (Gullick et al., 1986b ) and a 1.4Kb EcoRI fragment of the c-erbB-2 cDNA (Venter et al., 1987) . The blots were reprobed with genomic human alpha-2-1 and alpha-i-i collagen probes (situated on chromosomes 7 and 17 respectively), to estimate the amounts of DNA loaded . The blots were autoradiographed using Kodak XAR-5 film and the extent of amplification estimated by soft laser scanning densitometry.
PCR analysis of c-erbB-2 transmembrane region in tumour DNA DNA was prepared from primary brain tumours and then specifically amplified by the polymerase chain reaction as previously described (Lemoine et al., 1990a) using the oligonucleotides detailed in Hall et al. (1990) .
Results

EGF receptor
We examined the EGF receptor protein and its gene in a series of primary human tumour biopsies and in several brain tumour-derived cell lines (Table I ). In extracts of 14 primary tumours very variable levels of receptor protein expression was observed in the different samples by Western blotting employing either an antipeptide antibody to the receptor's ATP binding site (ISE, Gullick et al., 1986a, data not shown) or an antibody to a region between the kinase domain and the autophosphorylation site domain (2E, Gullick et al., 1986b) (Figure 1 ). Both antibodies however, gave consistant results. Immunoprecipitation and phosphorylation of immune complexes from tumour lysates showed concordant large variations in receptor expression (Figure 2 ) suggesting that the receptor was enzymatically active in these specimens. In each case preincubation of the immune complexes with a saturating concentration of EGF stimulated autophosphorylation (Figure 2 ) indicating that the receptor isolated from tumours 8 and 14 were activated by ligand binding. Lower exposure of the gel demonstrated that tumour 13 was also stimulated (data not shown).
It has been reported previously (Libermann et al., 1985; Wong et al., 1987) that the EGF receptor gene is commonly amplified in high grade gliomas. We therefore examined the EGF receptor gene structure and copy number by Southern blotting. Four of the 14 (29%) tumours examined displayed additional copies of the EGF receptor gene when compared to the single copy alpha-2-t and alpha-i-i collagen genes situated on chromosomes 7 and 17 respectively (Figure 3 ). There was no evidence of selective reduplication of chromosome 7 in any of these tumours, as determined by densitometric scanning of the autoradiographic signal produced by the alpha-2-1 and alpha-i-i collagen gene probes. With the one restriction enzyme employed there was no sign of gene rearrangement. In several cases there was a relationship between high levels of protein expression observed by Western blotting and/or kinase activity with amplification of the EGF receptor gene (Table II) . Tumour 8 and 13 however, appear to express high levels of receptor protein without evident gene amplification and tumour 9 gene amplification without grossly elevated levels of receptor protein. This discrepancy may be due to the necessity to use different fragments of the tumour in each assay system and the difficulty in reliably confirming the presence of tumour cells in each region of the biopsy.
Some reports have suggested that the EGF receptor is rarely overexpressed or its gene amplified in cell lines derived from brain tumours (Humphrey et al., 1988) . We therefore examined the expression of the EGF receptor in a series of 11 independently derived cell lines. Each line gave a surprisingly similar signal (data not shown) suggesting a low level of expression relative to A43 1 cell lysate used as a positive (Lehvaslaiho et al., 1989) . Autophosphorylation of the construct in response to EGF was employed as an indication of receptor activation. It was found that 3 mM MnCl2 gave maximal autophosphorylation but that MgCl2 did not support the reaction. Combinations of the two ions did not enhance autophosphorylation further. It was also found that maximal autophosphorylation was observed at room temperature and 15 min of incubation (data not shown). Despite several subsequent attempts employing these conditions no c-erbB-2 protein expression was detected in the tumour extracts. When the Southern blot shown in Figure 3 was reprobed to detect the c-erbB-2 gene no differences in fragment pattern or intensities were observed relative to normal DNA (data not shown), indicating no detectable gene rearrangement or amplification.
It was still possible, however, that the c-erbB-2 protein might be expressed at low levels in the tumours. Activating mutations in the transmembrane region of the rat neu gene have been observed which lead to cell transformation despite low levels of protein expression (Bargmann & Weinberg, 1988) . Similar mutations artifically introduced into human c-erbB-2 have the same effect (Segatto et al., 1988) . We therefore examined the sequence of the c-erbB-2 transmembrane region in DNA extracted from these tumours for the presence of such mutations. DNA was amplified by PCR and probed with wild type and mismatched oligonucleotides as described by Lemoine et al. (1990a) . No mutations were found in this region of the gene (data not shown).
We next examined the tumour cell lines for c-erbB-2 expression by Westem blotting. The c-erbB-2 protein was detected at variable but generally low levels in all of the cell lines tested. In one case, cell line lN/392 (Figure 4 , track 8), a somewhat higher level of c-erbB-2 protein was observed. Much less protein was seen however than present in extracts of the overexpressing breast cancer cell line SKBR-3 ( Figure  4 ). (Wells et al., 1988) . In another publication this line bound EGF which could be crosslinked to a protein of the same size as the EGF receptor, but the cells were unresponsive to EGF (Westphal et al., 1985) . In this study we found uniformly low levels of expression of EGF receptor protein in all the cell lines studied. It is possible that overexpression of EGF receptors in brain tumours is a selective advantage in vivo, but a disadvantage to cells in culture (Humphrey et al., 1988) and that mutation may have occurred in the EGF receptor gene in the SF268 cell line which inactivates the receptors catalytic activity (Wells et al., 1988) .
Overexpression of EGF receptors in breast cancer is associated with poor prognosis (Sainsbury et al., 1987) . It is not known whether overexpression in brain tumours defines a subgroup of tumours with different biological characteristics. Study of this is currently hampered by the lack of immunological reagents which reliably detect EGF receptor expression in paraffin embedded archival material. The high levels of receptor expression do however provide a target for immunoscintigraphy (Takahashi et al., 1987) and immunotherapy (Epenetos et al., 1985; Kalofonos et al., 1989) and novel forms of receptor inhibitors (Gullick, 1990 (Slamon et al., 1989; Gullick et al., 1990) , stomach (Falck & Gullick, 1989) and ovarian cancers (Slamon et al., 1989) and with a lower frequency in other tumour types (Hall et al., 1990; Yokota et al., 1986; Lemoine et al., 1990b) . The c-erbB-2 protein, detected by Western blotting, was expressed at low, variable levels in the cell lines, but not in the primary tumour biopsies. It may be that it is also expressed in the primary tumours, but at levels below our limit of detection. c-erbB-2 protein is normally expressed in some areas of foetal and adult (Quirke & Gullick, unpublished results) human brain.
We can conclude that amplification and overexpression of the c-erbB-2 protein is probably a rare event in human brain tumours, if it occurs at all. However, it was possible that low level expression of a mutant c-erbB-2 protein could occur and we therefore examined the gene for mutations at position 659 in the amino acid sequence. Previously this has been shown to occur in a rat carcinogenesis model leading to tumours of the CNS (Bargmann & Weinberg, 1988) and an equivalent change can convert the human gene-To a powerful oncogene (Segatto et al., 1988) . Using PCR and mismatched oligonucleotide hybridisation we saw no evidence of mutations in this region of the gene. Previously we have also found no mutations in a large series of breast (Lemoine et al., 1990a) , pancreatic (Hall et al., 1990) and thyroid tumours (Lemoine et al., 1990b however, expressed on normal cultured human glial cells (Heldin et al., 1981) , astrocytes (Richardson et al., 1988) and rat neurons (Smits et al., 1990) . Receptors are also present on transformed cell lines derived from gliomas (Nister et al., 1986; Nister et al., 1988 (Dicorleto & Bowen-Pope, 1983; Barrett et al., 1984; Collins et al., 1985) although this may be slightly different in structure to that made by glial cells (Tong et al., 1987) . Interestingly however, in situ hybridisation of three cases of glioblastoma multiforme revealed quite high levels of apparent PDGF receptor mRNA in proliferating tumour associated endothelial cells suggesting a possible autocrine or paracrine growth mechanism (Hermansson et al., 1988) . In this study we show that the PDGF receptor protein was present in several primary tumour extracts and was catalytically active. It was also present at low, variable levels in many of the cell lines examined indicating that the receptor was present in tumour cells. No reports have ever indicated that the PDGF receptor gene is amplified in any human tumours.
The critical question is whether either the production of PDGF or its receptors is abnormal in the tumours and is promoting their transformed phenotype. Detailed studies of the relative levels of receptor and ligand expression by normal and transformed cells are required to address this point. It seems however that there is circumstantial evidence for their involvement.
In summary, the EGF receptor gene is amplified and overexpressed in human brain tumours. From this work, however, it appears that although the c-erbB-2 protein is expressed in brain tumour cell lines, there is no evidence that this expression is abnormal. PDGF receptor expression could be demonstrated in human brain tumours and it may be that the PDGF system is influential in tumour cell growth regulation, but more experiments are required to address this issue.
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